Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver Disease.
Hannah M. Seagle, Alexis T. Akerele, Joseph A. DeCorte, Jacklyn N. Hellwege, Joseph H. Breeyear, Jeewoo Kim, Michael G. Levin, Samuel Khodurksy, Adam Phillip Bress, Kyung Min Lee, Jens Meiler, Dipender Gill, Jennifer S. Lee, Kent R. Heberer, Donald R. Miller, , Marijana Vujković
The paper identifies 57 druggable targets for MASLD using genetic data and evaluates their therapeutic potential through Mendelian randomization and structural modeling.
medRxiv · Feb 18, 2025 · PreprintGenetic & Genomic Medicine